

Seng Gee Lim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7657294/publications.pdf>

Version: 2024-02-01

173
papers

11,969
citations

36203

51
h-index

28224

105
g-index

177
all docs

177
docs citations

177
times ranked

12328
citing authors

#	ARTICLE	IF	CITATIONS
1	Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e228-e250.	2.4	17
2	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. <i>Hepatology International</i> , 2022, 16, 48-58.	1.9	7
3	Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy. <i>Hepatology International</i> , 2022, 16, 211-253.	1.9	21
4	Editorial: MAFLD and outcome prediction. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 737-738.	1.9	1
5	Phosphoproteomics Unravel HBV Triggered Rewiring of Host Phosphosignaling Events. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5127.	1.8	0
6	Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. <i>Journal of Hepatology</i> , 2022, 77, 967-977.	1.8	25
7	Impact of metabolic risk factors on the severity and outcome of patients with alcohol-associated acute-on-chronic liver failure. <i>Liver International</i> , 2021, 41, 150-157.	1.9	13
8	Identifying Patients With Cirrhosis Who Might Avoid Screening Endoscopy Based on Serum Albumin and Bilirubin and Platelet Counts. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 199-201.e2.	2.4	7
9	Bayesian analysis of cytokines and chemokine identifies immune pathways of HBsAg loss during chronic hepatitis B treatment. <i>Scientific Reports</i> , 2021, 11, 7455.	1.6	2
10	Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice. <i>Hepatology</i> , 2021, 74, 656-666.	3.6	31
11	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	0
12	Non-terminally exhausted tumor-resident memory HBV-specific T _H cell responses correlate with relapse-free survival in hepatocellular carcinoma. <i>Immunity</i> , 2021, 54, 1825-1840.e7.	6.6	64
13	Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma Immune Humanized Mouse Model. <i>Hepatology</i> , 2021, 74, 1395-1410.	3.6	25
14	Controversies in Treating Chronic Hepatitis B virus. <i>Clinics in Liver Disease</i> , 2021, 25, 763-784.	1.0	1
15	Novel albumin, bilirubin and platelet criteria for the exclusion of high-risk varices in compensated advanced chronic liver disease: A validation study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101598.	0.7	4
16	Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 1313-1325.	2.3	12
17	Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg). <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 172-182.	1.9	20
18	Editorial: Biomarkers in HBV and prediction of treatment response – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 334-334.	1.9	0

#	ARTICLE	IF	CITATIONS
19	Nucleoside analog monotherapy for prophylaxis in Hepatitis B liver transplant patients is safe and efficacious. <i>Hepatology International</i> , 2020, 14, 57-69.	1.9	11
20	CD4+ T Cells Mediate the Development of Liver Fibrosis in High Fat Diet-Induced NAFLD in Humanized Mice. <i>Frontiers in Immunology</i> , 2020, 11, 580968.	2.2	57
21	Glecaprevir+sofosbuvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 839-849.	3.7	32
22	The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: A systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2020, 27, 650-662.	1.0	16
23	A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma. <i>Nature Communications</i> , 2020, 11, 1556.	5.8	12
24	Hepatitis B: Who to treat? A critical review of international guidelines. <i>Liver International</i> , 2020, 40, 5-14.	1.9	25
25	Drug induced liver injury: East versus West—a systematic review and meta-analysis. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 142-154.	4.5	29
26	Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population. <i>World Journal of Hepatology</i> , 2020, 12, 1228-1238.	0.8	9
27	Life After s Loss: Impact of Hepatitis B s Antigen Loss on Future Patient Outcomes. <i>Clinical Liver Disease</i> , 2020, 16, 262-265.	1.0	2
28	THU-053-Usefulness of lactate-free Asian Pacific Association for The Study of Liver acute-on-chronic liver failure research consortium ACLF score for predicting short-term mortality in patient with alcoholic liver disease. <i>Journal of Hepatology</i> , 2019, 70, e184.	1.8	0
29	Risk factors for ribavirin treatment failure in Asian organ transplant recipients with chronic hepatitis E infection. <i>World Journal of Hepatology</i> , 2019, 11, 553-561.	0.8	6
30	A murine model demonstrating reversal of structural and functional correlates of cirrhosis with progenitor cell transplantation. <i>Scientific Reports</i> , 2019, 9, 15446.	1.6	11
31	THU-279-The prognostic stratification using acute-on-chronic liver failure scoring systems for predicting short-term mortality in patients with alcoholic hepatitis. <i>Journal of Hepatology</i> , 2019, 70, e285.	1.8	0
32	JNJ4178 (AL335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. <i>Hepatology</i> , 2019, 69, 2349-2363.	3.6	6
33	THU-045-Natural history of sepsis, organ failure and organ dysfunction in critically ill patients with acute on chronic liver failure. <i>Journal of Hepatology</i> , 2019, 70, e179-e180.	1.8	0
34	Multifactorial heterogeneity of virus-specific T cells and association with the progression of human chronic hepatitis B infection. <i>Science Immunology</i> , 2019, 4, .	5.6	57
35	Therapeutic vaccination for chronic hepatitis B: A systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2019, 26, 803-817.	1.0	32
36	Drug-Induced Acute-on-Chronic Liver Failure in Asian Patients. <i>American Journal of Gastroenterology</i> , 2019, 114, 929-937.	0.2	46

#	ARTICLE	IF	CITATIONS
37	Sofosbuvir+velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 127-134.	3.7	83
38	Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 45-51.	3.7	48
39	Challenges, Considerations, and Principles to Guide Trials of Combination Therapies for Chronic Hepatitis B Virus. <i>Gastroenterology</i> , 2019, 156, 529-533.e4.	0.6	13
40	Omega-6-derived oxylipin changes in serum of patients with hepatitis B virus-related liver diseases. <i>Metabolomics</i> , 2018, 14, 26.	1.4	13
41	Editorial: hepatocellular carcinoma risk in the era of direct-acting anti-virals "is the case closed?". <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 308-309.	1.9	0
42	Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. <i>Gut</i> , 2018, 67, 1845-1854.	6.1	134
43	Long-Term Fate of Human Fetal Liver Progenitor Cells Transplanted in Injured Mouse Livers. <i>Stem Cells</i> , 2018, 36, 103-113.	1.4	20
44	IDDF2018-ABS-0112...Safety and efficacy of sofosbuvir/velpatasvir in a genotype 1+6 hcv infected population from singapore, malaysia, thailand, and vietnam: results from a phase 3, clinical trial. , 2018, , .		2
45	IDDF2018-ABS-0067...Efficacy and safety of glecaprevir/pibrentasvir in patients with hcv genotype 5 or 6 infection: the endurance-5, 6 study. , 2018, , .		0
46	Findings from a large Asian chronic hepatitis C real-life study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1533-1542.	1.0	8
47	Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. <i>Journal of Clinical Investigation</i> , 2018, 128, 668-681.	3.9	167
48	Pathway to Hepatitis Elimination and Control. <i>Annals of the Academy of Medicine, Singapore</i> , 2018, 47, 435-437.	0.2	1
49	Management of hepatitis C virus infection in the Asia-Pacific region: an update. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 52-62.	3.7	45
50	HCV management in resource-constrained countries. <i>Hepatology International</i> , 2017, 11, 245-254.	1.9	10
51	Ethics and hepatitis B cure research. <i>Gut</i> , 2017, 66, 389-392.	6.1	13
52	When can we stop nucleoside analogues in patients with chronic hepatitis B?. <i>Liver International</i> , 2017, 37, 52-58.	1.9	24
53	Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease. <i>Journal of Hepatology</i> , 2017, 67, 490-500.	1.8	55
54	Modulating Hepatocellular Carcinoma Biology with Amniotic Epithelial Cell via Reversal of Epithelial Mesenchymal Transition. <i>Gastroenterology</i> , 2017, 152, S296.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. <i>Hepatology International</i> , 2017, 11, 1-30.	1.9	178
56	Advancing the regulatory path on hepatitis B virus treatment and curative research: a stakeholders consultation. <i>Journal of Virus Eradication</i> , 2017, 3, 1-6.	0.3	5
57	Single-virion sequencing of lamivudine-treated HBV populations reveal population evolution dynamics and demographic history. <i>BMC Genomics</i> , 2017, 18, 829.	1.2	6
58	Magnetic Resonance Elastography and Diffusion Weighted Imaging in the Evaluation of Hepatic Fibrosis in Chronic Hepatitis B. <i>Gut and Liver</i> , 2017, 11, 401-408.	1.4	32
59	Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1628-1637.	1.4	10
60	World Gastroenterology Organisation Global Guideline Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 691-703.	1.1	14
61	Overexpression of Tyro3 and its implications on hepatocellular carcinoma progression. <i>International Journal of Oncology</i> , 2016, 48, 358-366.	1.4	29
62	Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). <i>Journal of Hepatology</i> , 2016, 64, 1011-1019.	1.8	84
63	Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2016, 64, 773-780.	1.8	223
64	Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection. <i>Gut</i> , 2016, 65, 1744-1753.	6.1	34
65	Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders. <i>Gut</i> , 2016, 65, 340-350.	6.1	62
66	Time for Action on Viral Hepatitis. <i>Annals of the Academy of Medicine, Singapore</i> , 2016, 45, 27-30.	0.2	3
67	Hepatitis B immunoprophylaxis failure and the presence of hepatitis B surface gene mutants in the affected children. <i>Journal of Medical Virology</i> , 2015, 87, 1344-1350.	2.5	15
68	Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-pacific hepatitis C virus genotype 1 non-responders/relapsers. <i>World Journal of Gastroenterology</i> , 2015, 21, 8660.	1.4	5
69	Reimbursement policies in the Asia-Pacific for chronic hepatitis B. <i>Hepatology International</i> , 2015, 9, 43-51.	1.9	20
70	Hepatic differentiation of human amniotic epithelial cells and <i>in vivo</i> therapeutic effect on animal model of cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1673-1682.	1.4	35
71	Hepatitis C: An Eastern Perspective. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 793-805.	1.0	4
72	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. <i>Journal of Hepatology</i> , 2015, 62, 41-47.	1.8	59

#	ARTICLE	IF	CITATIONS
73	Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings. World Journal of Gastroenterology, 2015, 21, 1972.	1.4	9
74	A 2015 roadmap for the management of hepatitis C virus infections in Asia. Korean Journal of Internal Medicine, 2015, 30, 423.	0.7	19
75	Search for a cure for chronic hepatitis B infection: How close are we?. World Journal of Hepatology, 2015, 7, 1272.	0.8	15
76	RPL39L is an example of a recently evolved ribosomal protein paralog that shows highly specific tissue expression patterns and is upregulated in ESCs and HCC tumors. RNA Biology, 2014, 11, 33-41.	1.5	59
77	BAse-Seq: a method for obtaining long viral haplotypes from short sequence reads. Genome Biology, 2014, 15, 517.	3.8	45
78	Editorial: patients' preferences and health utility assessment in those with HCV treated with sofosbuvir - stating the obvious?. Alimentary Pharmacology and Therapeutics, 2014, 40, 1115-1115.	1.9	1
79	Clinical significance of hepatitis B virion and SVP productivity: relationships between intrahepatic and serum markers in chronic hepatitis B patients. United European Gastroenterology Journal, 2014, 2, 99-107.	1.6	10
80	Telbivudine Improves Renal Function in Patients With Chronic Hepatitis B. Gastroenterology, 2014, 146, 138-146.e5.	0.6	99
81	Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. European Radiology, 2014, 24, 70-78.	2.3	147
82	Commentary: vitamin D deficiency and liver cancer – cause, effect or myth?. Alimentary Pharmacology and Therapeutics, 2014, 39, 1429-1429.	1.9	1
83	Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. Hepatology International, 2014, 8, 382-394.	1.9	9
84	Reduction of HBV replication prolongs the early immunological response to IFN α therapy. Journal of Hepatology, 2014, 60, 54-61.	1.8	75
85	Patient Preferences for Hepatitis B Therapy. Antiviral Therapy, 2013, 18, 663-670.	0.6	19
86	Are physicians following guidelines? A survey of Hepatitis B management strategies. Hepatology International, 2013, 7, 451-459.	1.9	5
87	Resistance is no Longer a Problem with Entecavir and Tenofovir. Current Hepatitis Reports, 2013, 12, 96-104.	0.3	0
88	The p7 protein of the hepatitis C virus induces cell death differently from the influenza A virus viroporin M2. Virus Research, 2013, 172, 24-34.	1.1	29
89	Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?. Journal of Medical Virology, 2013, 85, 26-33.	2.5	8
90	Increased viral quasispecies evolution in HBeAg seroconverter patients treated with oral nucleoside therapy. Journal of Hepatology, 2013, 58, 217-224.	1.8	28

#	ARTICLE	IF	CITATIONS
91	Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 710-719.	1.9	18
92	Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion. <i>Gut</i> , 2013, 62, 1347-1355.	6.1	35
93	Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. <i>Journal of Clinical Investigation</i> , 2013, 123, 3766-3776.	3.9	80
94	Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. <i>Molecular Cancer</i> , 2012, 11, 14.	7.9	63
95	Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. <i>Gastrointestinal Endoscopy</i> , 2012, 76, 756-760.	0.5	108
96	Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2012, 18, 3527.	1.4	29
97	Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. <i>Journal of Hepatology</i> , 2011, 55, 103-110.	1.8	183
98	Clinical Outcomes of Lamivudine-Adefovir Therapy in Chronic Hepatitis B Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 818-823.	1.1	9
99	Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. <i>Liver International</i> , 2011, 31, 755-761.	1.9	66
100	Risk factors for mortality in cirrhotic patients with sepsis. <i>Hepatology International</i> , 2011, 5, 800-807.	1.9	11
101	Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. <i>Hepatology International</i> , 2010, 4, 386-395.	1.9	47
102	Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. <i>Hepatology International</i> , 2010, 4, 439-474.	1.9	944
103	PCBP1 Suppresses the Translation of Metastasis-Associated PRL-3 Phosphatase. <i>Cancer Cell</i> , 2010, 18, 52-62.	7.7	155
104	Reliability and Validity of a Chinese Version's Health-Related Quality of Life Questionnaire for Hepatitis B Patients. <i>Value in Health</i> , 2010, 13, 324-327.	0.1	7
105	C/EBP β Is Up-regulated in a Subset of Hepatocellular Carcinomas and Plays a Role in Cell Growth and Proliferation. <i>Gastroenterology</i> , 2010, 139, 632-643.e4.	0.6	45
106	A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. <i>Journal of Hepatology</i> , 2010, 52, 330-339.	1.8	141
107	Serum autoantibodies as biomarkers for early cancer detection. <i>FEBS Journal</i> , 2009, 276, 6880-6904.	2.2	272
108	Prevention of hepatocellular carcinoma in hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1352-1357.	1.4	67

#	ARTICLE	IF	CITATIONS
109	Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. <i>Journal of Hepatology</i> , 2009, 50, 118-127.	1.8	163
110	Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2009, 137, 682-690.	0.6	152
111	The economics of treating chronic hepatitis B in Asia. <i>Hepatology International</i> , 2008, 2, 284-295.	1.9	32
112	2D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis. <i>Proteomics</i> , 2008, 8, 5086-5096.	1.3	41
113	Comparing the antibody responses against recombinant hemagglutinin proteins of avian influenza A (H5N1) virus expressed in insect cells and bacteria. <i>Journal of Medical Virology</i> , 2008, 80, 1972-1983.	2.5	35
114	Health-related quality of life in chronic hepatitis B patients. <i>Hepatology</i> , 2008, 47, 1108-1117.	3.6	96
115	Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 1282-1292.	1.9	25
116	Rac1 GTPase is activated by hepatitis B virus replication - involvement of HBX. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2008, 1783, 360-374.	1.9	29
117	Hepatitis B pregenomic RNA splicing - The products, the regulatory mechanisms and its biological significance. <i>Virus Research</i> , 2008, 136, 1-7.	1.1	30
118	Telbivudine: a hepatitis B-specific antiviral. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 217-229.	1.3	0
119	Host Ethnicity and Virus Genotype Shape the Hepatitis B Virus-Specific T-Cell Repertoire. <i>Journal of Virology</i> , 2008, 82, 10986-10997.	1.5	114
120	Heplisavac: a new hepatitis B vaccine. <i>Future Virology</i> , 2008, 3, 109-117.	0.9	1
121	Molecular and functional characterization of drug-metabolizing enzymes and transporter expression in the novel spontaneously immortalized human hepatocyte line HC-04. <i>Toxicology in Vitro</i> , 2007, 21, 1390-1401.	1.1	32
122	Viral Quasi-Species Evolution During Hepatitis Be Antigen Seroconversion. <i>Gastroenterology</i> , 2007, 133, 951-958.	0.6	120
123	The use of hepatitis C virus NS3/4A and secreted alkaline phosphatase to quantitate cell-cell membrane fusion mediated by severe acute respiratory syndrome coronavirus S protein and the receptor angiotensin-converting enzyme 2. <i>Analytical Biochemistry</i> , 2007, 366, 190-196.	1.1	3
124	Regulation of cell death during infection by the severe acute respiratory syndrome coronavirus and other coronaviruses. <i>Cellular Microbiology</i> , 2007, 9, 2552-2561.	1.1	35
125	Applicability of cost-effectiveness analysis to management of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1357-1359.	1.4	1
126	Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1419-1428.	1.9	29

#	ARTICLE	IF	CITATIONS
127	Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years. <i>Gastroenterology</i> , 2006, 131, 1743-1751.	0.6	832
128	Population Pharmacokinetics of Tacrolimus in Whole Blood and Plasma in Asian Liver Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2006, 45, 59-75.	1.6	59
129	Severe acute respiratory syndrome coronavirus protein 7a interacts with hSGT. <i>Biochemical and Biophysical Research Communications</i> , 2006, 343, 1201-1208.	1.0	40
130	ACE2 orthologues in non-mammalian vertebrates (Danio, Gallus, Fugu, Tetraodon and Xenopus). <i>Gene</i> , 2006, 377, 46-55.	1.0	31
131	Non-invasive models for predicting histology in patients with chronic hepatitis B. <i>Liver International</i> , 2006, 26, 666-672.	1.9	115
132	Are in vitro hepatitis B core promoter mutations important for clinical alterations in viral load? <i>Antiviral Research</i> , 2006, 69, 142-151.	1.9	9
133	Synthesis and the biological evaluation of 2-benzenesulfonylalkyl-5-substituted-sulfonyl-[1,3,4]-oxadiazoles as potential anti-hepatitis B virus agents. <i>Antiviral Research</i> , 2006, 71, 7-14.	1.9	130
134	Prophylactic strategies for hepatitis B patients undergoing liver transplant: A cost-effectiveness analysis. <i>Liver Transplantation</i> , 2006, 12, 736-746.	1.3	64
135	Understanding Human Immunodeficiency Virus Type 1 and Hepatitis C Virus Coinfection. <i>Current HIV Research</i> , 2006, 4, 21-30.	0.2	17
136	Randomized, Double-Blind Study of Emtricitabine (FTC) plus Clevudine versus FTC Alone in Treatment of Chronic Hepatitis B. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1642-1648.	1.4	48
137	A Double-blind Placebo-Controlled Study of Emtricitabine in Chronic Hepatitis B. <i>Archives of Internal Medicine</i> , 2006, 166, 49.	4.3	134
138	Use of an in vitro Model and Yeast Two-Hybrid System to Investigate the Pathogenesis of Hepatitis C. <i>Intervirology</i> , 2006, 49, 44-50.	1.2	5
139	Monoclonal Antibodies Targeting the HR2 Domain and the Region Immediately Upstream of the HR2 of the S Protein Neutralize In Vitro Infection of Severe Acute Respiratory Syndrome Coronavirus. <i>Journal of Virology</i> , 2006, 80, 941-950.	1.5	99
140	A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 245-53.	0.6	6
141	A Randomized, Placebo-Controlled Trial of Thymosin- α 1 and Lymphoblastoid Interferon for Hbeag-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 245-254.	0.6	16
142	Factors influencing stem cell differentiation into the hepatic lineage <i>in vitro</i> . <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 975-987.	1.4	25
143	Characterization of viral proteins encoded by the SARS-coronavirus genome. <i>Antiviral Research</i> , 2005, 65, 69-78.	1.9	101
144	A novel cell-based binding assay system reconstituting interaction between SARS-CoV S protein and its cellular receptor. <i>Journal of Virological Methods</i> , 2005, 123, 41-48.	1.0	22

#	ARTICLE	IF	CITATIONS
145	Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2005, 352, 2673-2681.	13.9	524
146	The Severe Acute Respiratory Syndrome Coronavirus 3a Protein Up-Regulates Expression of Fibrinogen in Lung Epithelial Cells. <i>Journal of Virology</i> , 2005, 79, 10083-10087.	1.5	64
147	The severe acute respiratory syndrome coronavirus 3a is a novel structural protein. <i>Biochemical and Biophysical Research Communications</i> , 2005, 330, 286-292.	1.0	90
148	Amino Acids 1055 to 1192 in the S2 Region of Severe Acute Respiratory Syndrome Coronavirus S Protein Induce Neutralizing Antibodies: Implications for the Development of Vaccines and Antiviral Agents. <i>Journal of Virology</i> , 2005, 79, 3289-3296.	1.5	102
149	Genetic lesions within the 3a gene of SARS-CoV. <i>Virology Journal</i> , 2005, 2, 51.	1.4	7
150	Characterization of a Unique Group-Specific Protein (U122) of the Severe Acute Respiratory Syndrome Coronavirus. <i>Journal of Virology</i> , 2004, 78, 7311-7318.	1.5	67
151	A Novel Severe Acute Respiratory Syndrome Coronavirus Protein, U274, Is Transported to the Cell Surface and Undergoes Endocytosis. <i>Journal of Virology</i> , 2004, 78, 6723-6734.	1.5	149
152	Profiles of Antibody Responses against Severe Acute Respiratory Syndrome Coronavirus Recombinant Proteins and Their Potential Use as Diagnostic Markers. <i>Vaccine Journal</i> , 2004, 11, 362-371.	2.6	163
153	Cellular RNA Helicase p68 Relocalization and Interaction with the Hepatitis C Virus (HCV) NS5B Protein and the Potential Role of p68 in HCV RNA Replication. <i>Journal of Virology</i> , 2004, 78, 5288-5298.	1.5	111
154	Overexpression of 7a, a Protein Specifically Encoded by the Severe Acute Respiratory Syndrome Coronavirus, Induces Apoptosis via a Caspase-Dependent Pathway. <i>Journal of Virology</i> , 2004, 78, 14043-14047.	1.5	189
155	Histone H4 histidine kinase displays the expression pattern of a liver oncodevelopmental marker. <i>Carcinogenesis</i> , 2004, 25, 2083-2088.	1.3	41
156	Practical difficulties in the management of hepatitis B in the Asia-Pacific region. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 958-969.	1.4	51
157	A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. <i>Hepatology</i> , 2004, 40, 719-726.	3.6	96
158	Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity. <i>Biochemical Journal</i> , 2004, 384, 401-409.	1.7	40
159	Proteomic approach identifies HSP27 as an interacting partner of the hepatitis C virus NS5A protein. <i>Biochemical and Biophysical Research Communications</i> , 2004, 318, 514-519.	1.0	45
160	CD81 engineered with endocytotic signals mediates HCV cell entry: implications for receptor usage by HCV in vivo. <i>Virology</i> , 2003, 308, 250-269.	1.1	21
161	An anti-HIV-1 gp120 antibody expressed as an endocytotic transmembrane protein mediates internalization of HIV-1. <i>Virology</i> , 2003, 315, 80-92.	1.1	6
162	Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2003, 348, 808-816.	13.9	1,297

#	ARTICLE	IF	CITATIONS
163	Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen-“Negative Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2003, 348, 800-807.	13.9	971
164	Intracellular Inhibition of Hepatitis B Virus S Gene Expression by Chimeric DNA-RNA Phosphorothioate Minimized Ribozyme. <i>Oligonucleotides</i> , 2002, 12, 257-264.	4.4	10
165	Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. <i>Gut</i> , 2002, 51, 597-599.	6.1	103
166	Diagnostic yield of upper endoscopy in Asian patients presenting with dyspepsia. <i>Gastrointestinal Endoscopy</i> , 2002, 56, 548-551.	0.5	44
167	Histological improvement in HBeAg positive chronic hepatitis B patients treated with adefovir dipivoxil. <i>Journal of Hepatology</i> , 2002, 36, 8.	1.8	3
168	Second-phase viral clearance as a measure for dose optimization of anti-HBV nucleosides. <i>Journal of Hepatology</i> , 2002, 36, 115.	1.8	1
169	Expression of a Full-Length Hepatitis C Virus cDNA Up-Regulates the Expression of CC Chemokines MCP-1 and RANTES. <i>Virology</i> , 2002, 303, 253-277.	1.1	56
170	Inducible System in Human Hepatoma Cell Lines for Hepatitis C Virus Production. <i>Virology</i> , 2002, 303, 79-99.	1.1	16
171	The Hepatitis C Virus Core Protein Interacts with NS5A and Activates Its Caspase-Mediated Proteolytic Cleavage. <i>Virology</i> , 2001, 290, 224-236.	1.1	51
172	Identification and molecular characterisation of the complete genome of a Singapore isolate of hepatitis C virus: sequence comparison with other strains and phylogenetic analysis. <i>Virus Genes</i> , 2001, 23, 89-95.	0.7	12
173	Mutations That Affect Dimer Formation and Helicase Activity of the Hepatitis C Virus Helicase. <i>Journal of Virology</i> , 2001, 75, 205-214.	1.5	35